Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on H acid. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN112041298A details a safe, efficient route for aromatic nitriles via Willgerodt rearrangement. Reduces sulfur impurities and avoids toxic cyanides for pharma intermediates.
Patent CN102093399B reveals stable boronation reagent synthesis. Offers cost reduction and supply reliability for high-purity pharmaceutical intermediates manufacturing.
Novel one-pot Grignard method for alkyl phenylboronic acid reduces cost and time. Ideal for high-purity pharmaceutical and agrochemical intermediate manufacturing.
Patent CN103687489A reveals a safer, scalable route for 5-azaspiro[2.4]heptane-6-carboxylic acid, eliminating pyrophoric reagents for reliable HCV inhibitor supply.
Novel salt formation method removes dicarboxylic acid impurity ensuring high purity and yield for scalable antihypertensive drug manufacturing.
Patent CN110004119B discloses a thermostable epsilon-ketoester reductase mutant enabling efficient synthesis of (R)-alpha-lipoic acid precursors with reduced catalyst loading and enhanced stability.
Patent CN113801045A details a novel Pd-catalyzed carbonylation route for 2-nitro-4-methylsulfonylbenzoic acid, offering safer, high-purity production for agrochemical supply chains.
Patent CN102317248A details an efficient route for (S)-3-cyclohexene-1-carboxylic acid, a key FXa inhibitor intermediate, offering significant cost and supply chain advantages.
Patent CN108069882A reveals continuous catalytic hydrogenation for anthranilic acid. Enhances purity and supply chain reliability for dye manufacturers significantly.
Patented chiral resolution process ensures high purity S-tetrahydro-2-furoic acid. Cost-effective manufacturing and reliable supply chain for global pharmaceutical partners.
Patent CN112359036B discloses engineered nitrilase mutants for efficient synthesis of pregabalin chiral intermediates, offering significant cost reduction in API manufacturing.
Patent CN113480589B details a novel DMAP salt method for UDCA purification ensuring high yield and purity for reliable pharmaceutical intermediate supply chains.
Novel Pd-Pt-Zn catalyst enables 98% CHDA selectivity. Reduces decarboxylation. Ideal for reliable fine chemical intermediate supplier partnerships.
Discover a novel L-glutamic acid route for multi-chiral tetrahydrofuran rings. High stereoselectivity and mild conditions for cost-effective API manufacturing.
Patent CN102391243A details a novel 7-step synthesis for Atorvastatin intermediates, eliminating expensive lithium reagents and improving supply chain reliability.
Patent CN111349014A reveals a safer, high-yield route for Methyl (methylamino)squarate, eliminating hazardous solvents and reducing manufacturing costs for global supply chains.
Patent CN110878064A reveals a breakthrough synthesis route for febuxostat impurities, boosting total yield from 0.2% to 43% via strategic intermediate sequencing.
Novel 5-step synthesis from D-Glutamic acid for DPP-IV inhibitors. High yield, mild conditions, and cost-effective industrial manufacturing process.
Patent CN116120325B reveals a novel preparation method for Ketorolac EP Impurity D with high purity and simplified operations for reliable pharmaceutical intermediates supply chains.
Novel dibromo-amino silica gel method achieves >99% selectivity and >99.8% purity for SGLT-2 inhibitors, significantly reducing waste and manufacturing costs.